PUR 003

Drug Profile

PUR 003

Alternative Names: PUR003

Latest Information Update: 22 Sep 2015

Price : $50

At a glance

  • Originator Pulmatrix
  • Class Antivirals
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Influenza virus infections

Most Recent Events

  • 21 May 2012 Pharmacodynamics and tolerability data from a phase I trial in Asthma released by Pulmatrix
  • 15 Dec 2010 Pulmatrix receives grant from US Department of Defense for development of inhaled Cationic Airway Modulator (iCALM) products for infections
  • 27 Apr 2010 Pulmatrix completes a phase I trial in Healthy volunteers in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top